Literature DB >> 1469796

Prognosis of osteosarcoma treated by limb-salvage surgery: the ten-year intergroup study in Japan.

H Tsuchiya1, K Tomita.   

Abstract

We report the prognoses for 107 patients treated by limb-salvage surgery and 147 treated by amputation or disarticulation, during the period 1980-1985, at 22 university hospitals, cancer centers and national hospitals in Japan. In this multi-institute non-randomized study, the five-year cumulative survival rate was 70% for the former group and 49% for the latter. The prognosis was more favorable among patients who responded to preoperative chemotherapy than among those who did not. Limb-salvage surgery was feasible for most of the surgical stage IIB patients with small extraosseous tumor extensions who had responded to preoperative chemotherapy. Local tumor recurrences were seen in 15 (14%) of the 107 patients in the limb-salvage surgery group, nine of whom died of the metastasis. While limb-salvage surgery is being increasingly used in Japan, present indications show the procedure not to reduce survival rate for osteosarcoma patients. The survival rate of patients with wide-with-marginal margins was similar to that of patients with wide margins. Taking into account the long-term survival of osteosarcoma patients, limb-salvage surgery can be recommended when the osteosarcoma responds to preoperative chemotherapy.

Entities:  

Mesh:

Year:  1992        PMID: 1469796

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  8 in total

1.  Limb Salvage Versus Amputation in Conventional Appendicular Osteosarcoma: a Systematic Review.

Authors:  Julio J Jauregui; Vidushan Nadarajah; Joseph Munn; Robert Pivec; Bhaveen H Kapadia; Daniel M Lerman; Aditya V Maheshwari
Journal:  Indian J Surg Oncol       Date:  2018-01-20

Review 2.  Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis.

Authors:  Evgenia Papakonstantinou; Alexandros Stamatopoulos; Dimitrios I Athanasiadis; Efstathios Kenanidis; Michael Potoupnis; Anna-Bettina Haidich; Eleftherios Tsiridis
Journal:  J Bone Oncol       Date:  2020-09-15       Impact factor: 4.072

Review 3.  Amputation Versus Limb-Salvage Surgery in Patients with Osteosarcoma: A Meta-analysis.

Authors:  Gang Han; Wen-Zhi Bi; Meng Xu; Jin-Peng Jia; Yan Wang
Journal:  World J Surg       Date:  2016-08       Impact factor: 3.352

4.  The Significance of a "Close" Margin in Extremity Sarcoma: A Systematic Review.

Authors:  Ike Hasley; Yubo Gao; Amy E Blevins; Benjamin J Miller
Journal:  Iowa Orthop J       Date:  2018

5.  Prognostic factors and treatment results of high-grade osteosarcoma in norway: a scope beyond the "classical" patient.

Authors:  Kjetil Berner; Kirsten Sundby Hall; Odd R Monge; Harald Weedon-Fekjær; Olga Zaikova; Øyvind S Bruland
Journal:  Sarcoma       Date:  2015-02-17

6.  Treatment-Related Prognostic Factors in Managing Osteosarcoma around the Knee with Limb Salvage Surgery: A Lesson from a Long-Term Follow-Up Study.

Authors:  Jianping Hu; Chunlin Zhang; Kunpeng Zhu; Lei Zhang; Tao Cai; Taicheng Zhan; Xiong Luo
Journal:  Biomed Res Int       Date:  2019-05-02       Impact factor: 3.411

7.  Dual-functional porous and cisplatin-loaded polymethylmethacrylate cement for reconstruction of load-bearing bone defect kills bone tumor cells.

Authors:  Zhule Wang; Liebert Parreiras Nogueira; Håvard Jostein Haugen; Ingrid Cm Van Der Geest; Patricia Caetano de Almeida Rodrigues; Dennis Janssen; Thom Bitter; Jeroen J J P van den Beucken; Sander Cg Leeuwenburgh
Journal:  Bioact Mater       Date:  2021-12-29

Review 8.  A comparative study between limb-salvage and amputation for treating osteosarcoma.

Authors:  Xiaojuan Li; Ya Zhang; Shanshan Wan; Huiling Li; Dongqi Li; Junfeng Xia; Zhongqin Yuan; Mingyan Ren; Shunling Yu; Su Li; Yihao Yang; Lei Han; Zuozhang Yang
Journal:  J Bone Oncol       Date:  2016-01-23       Impact factor: 4.072

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.